Keystone Bio Adds Significant Scientific Leadership with Appointment of Medical Advisor and New Scientific Advisory Board Members


ST. LOUIS–()–Keystone Bio, a clinical-stage biotechnology company working to stop inflammatory diseases at their source, today announced the appointment of Michael Rafii, MD, Ph.D., as Medical Advisor major in neurology. The company also announced a new Scientific Advisory Board (SAB) comprised of members bringing expertise in microbiology and downstream inflammatory processes, including cardio-metabolic and neuro-inflammatory diseases.

Keystone Bio is taking a new approach to developing companion therapies and diagnostics targeting Porphyromonas gingivalis (Pg), which causes a widespread chronic infection in the mouth. Pg releases toxins into the bloodstream, triggering inflammation throughout the body and leading to chronic diseases such as cardio-metabolic and vascular diseases as well as dementias such as Alzheimer’s disease.

“We are delighted to have Mike join Keystone’s scientific leadership team and share his extensive experience in Alzheimer’s disease research and multi-center clinical trials,” said Daniel Sindelar, DMD, CEO of Keystone Bio. “With the addition of Mike, we continue to build on the expertise of our world-class group of chronic inflammatory disease experts, with the ultimate goal of stopping the disease at its source.”

Dr. Rafii is a board-certified neurologist, medical director of the Alzheimer’s Disease Therapeutic Research Institute (ATRI), and professor of neurology at the University of Southern California’s Keck School of Medicine. His work has been featured in the New York Times, Chicago Tribune, Washington Post and the wall street journal and on National Public Radio (NPR). Rafii earned an MD and Ph.D. from Brown University and completed a neurology residency at Johns Hopkins University School of Medicine and a fellowship in neurodegenerative diseases at the University of California, San Diego School of Medicine.

Dr. Rafii joins Daniel Sindelar, DMD, CEO; Marc Penn, MD, Ph.D., chief medical officer; Peter Nara, DVM, Ph.D., Scientific Director; and Garth D. Ehrlich, Ph.D., FAAS, FAAM, president of SAB; as a consultant within the management team of Keystone Bio.

Additionally, Keystone Bio announced the formation of a new Scientific Advisory Board, comprised of members such as:

  • Garth D. Ehrlich, Ph.D., FAAAS, FAAM, Executive Director of the Center for Genomic Sciences, Executive Director of the Center for Advanced Microbial Processing, and Executive Director of the Center for Surgical Infections and Biofilms within the Institute of Molecular Medicine and Infectious Diseases at Drexel College of Medicine. In addition, Dr. Ehrlich is Director of the Drexel Medicine Diagnostics Genomics Platform and New Laboratory. To his role as CCS Chair, Dr. Ehrlich brings a lifetime of experience in molecular medicine, genomic science and molecular diagnostics of infectious diseases.
  • Rita Colwell, Ph.D.Fellow of the National Academy of Sciences, Professor Emeritus of the University of Maryland College Park and Johns Hopkins University Bloomberg School of Public Health, Senior Advisor and Chairman Emeritus of Canon US Life Sciences, Inc., and Chairman and President of CosmosID, Inc. Dr. Colwell was the eleventh director of the National Sciences Foundation and was awarded the 2006 National Medal of Science. She brings to her role extensive experience in global infectious disease policy and research and a sense of acute of the scientific council.
  • Robert Rissman, Ph.D., professor of neuroscience and director of the Neuropathology and Biomarkers Nuclei of the Alzheimer’s Disease Research Center (ADRC) at the University of California, San Diego. Dr. Rissman is lead of the Biomarkers Unit for the NIA’s Alzheimer’s Disease Clinical Trials Consortium (ACTC) through the Alzheimer’s Disease Therapeutic Research Institute (ATRI) of the University of Southern California (USC). He brings significant experience in the diagnosis of neurodegenerative diseases, including Alzheimer’s disease.
  • Jan Potempa, Ph.D., D.Sc., a research professor at Jagiellonian University and a professor and research fellow at the University of Louisville School of Dentistry. Dr. Potempa brings his expertise in Porphyromonas gingivalis (Pg) biology has its role.
  • Shaun Lonergan, MS, CEO of Precion LLC. Lonergan shares its in-depth knowledge of diagnostics for disease detection.
  • W. Sue T. Griffin, Ph.D., Alexa and William T. Dillard Professor and Vice Chair of Research at the Donald W. Reynolds Department of Geriatrics at the University of Arkansas for Medical Sciences; Director of Research, Geriatric Research Education and Clinical Center, Central Arkansas Veterans Health System; and editor of the Journal of Neuroinflammation. In her role, Dr. Griffin offers in-depth expertise in neuroinflammation and its impact on Alzheimer’s disease.
  • Edward J. Zuckerberg, DDS, FAGD, CEO and Founder of Painless Social Media LLC and Venture Partner at Revere Partners. Dr. Zuckerberg shares his experience in dentistry, periodontal disease and social media.

“Keystone’s leadership team and Scientific Advisory Board (SAB) collectively include experts in inflammation, Alzheimer’s disease and other neurological diseases, cardio-metabolic diseases, infectious diseases, large-scale genomics and dentistry,” said Daniel Sindelar, DMD, CEO of Keystone Bio. “With the creation of our new SAB, we bring a wealth of perspective and experience to our unique approach to early intervention in devastating inflammatory diseases.”

About Keystone Bio

Keystone Bio is advancing new therapies and companion diagnostics to stop a primary driver of systemic inflammation, the root cause of many neurodegenerative and vascular diseases affecting hundreds of millions of people.

Our lead monoclonal antibody has been shown to eradicate Porphyromonas gingivalis (Pg) at its source, stopping the daily flow of its highly virulent and pathogenic toxins throughout the body. Our team of entrepreneurs and scientists, including global experts in Pg, Alzheimer’s disease, cardio-metabolic diseases and dentistry, are working to stop the disease at its source.


Comments are closed.